We are pleased that recruitment is now underway on an ongoing basis at 25 clinical sites across the United States of the phase 11a trial to assess the safety and tolerability of Nilotinib in Parkinson's.  The Michael J Fox Foundation (MJFF) has collaborated with Van Andel Research Institute(VARI) and The Cure Parkinson's Trust(CPT) toward the development and launch of this clinical trial.

Read more of the background to this trial here.

Nilotinib, a U.S. Food and Drug Administration (FDA)-approved treatment for chronic myelogenous leukemia, is one of many examples of a repurposed drug for Parkinson's (PD). Repurposing is a promising and relatively efficient way to seed the pipeline of drugs by taking an existing medicine approved for one condition and using it to treat another - it is an area of research which CPT is particularly focused on. Repurposed drugs can usually skip Phase I clinical testing because they are already proven safe in humans. However, Phase II and Phase III trials are required to rigorously evaluate these treatments in PD.

"Repurposing is a promising path to new PD treatments, but we must demonstrate the safety and efficacy of therapies specifically for PD," says Todd Sherer, PhD, CEO at MJFF. "As part of our 'no-stone-unturned' approach, The Michael J. Fox Foundation pursues every avenue, including repurposing, to accelerate breakthroughs for patients who urgently need them."

Patients and clinicians are urged to wait for additional data before adding Nilotinib or any other repurposed treatments to their regimen. 

Read the trial details here: https://clinicaltrials.gov/ct2/show/NCT03205488

Read the MJFF full press release.